| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5604130 | International Journal of Cardiology | 2017 | 8 Pages |
Abstract
This first randomized controlled study for the topical use of the hemostatic agent PerClot® in CRD implantation was terminated early by the safety monitoring board because of an augmented rate of fever and inflammatory markers in the PerClot® group. The addition of PerClot® does not suggest a benefit with regard to the frequency of pocket hematoma.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Verena Tscholl, Felicitas Spann, Jane Moses, Patrick Nagel, Barbara Bellmann, Sebastian Biewener, Marie Amtenbrink, Stroux Andrea, Andreas Rillig, Ulf Landmesser, Mattias Roser,